Lysozyme-Chitosan Complex Suppresses Neutrophil Adhesion
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for neutrophil-induced inflammation, such as those caused by excessive reactive oxygen species production, often result in adverse effects on cellular tissues, and existing solutions like glucosamine and plant essential oils have limitations in effectively suppressing neutrophil activation and adhesion.
Innovation Solution
A pharmaceutical composition containing a complex of lysozyme and chitosan bound together, which is produced through the Maillard reaction or cross-linking, is used to suppress neutrophil adhesion and subsequent inflammatory reactions by masking antigenic structures and potentially incorporating terpene alcohols, fatty acids, or their salts.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If glucosamine or plant essential oils are used to suppress neutrophil activation, then inflammatory reactions are reduced, but the effectiveness in suppressing excessive reactive oxygen species production is insufficient
Solution Approach 1:
The patent combines lysozyme and chitosan to form a composite material that exhibits synergistic effects. Lysozyme provides antimicrobial and anti-inflammatory properties, while chitosan contributes to immunomodulation and reactive oxygen species scavenging. This composite approach enhances the overall effectiveness in suppressing neutrophil activation and reactive oxygen species production compared to single substances like glucosamine or plant essential oils.
Solution Approach 2:
The patent optimizes the molecular weight of chitosan (1,000-30,000 Da) and the concentration ratio of lysozyme to chitosan (1:9 to 9:1) to achieve maximum therapeutic effect. These parameter adjustments enhance the ability of the complex to suppress neutrophil activation and reactive oxygen species production, addressing the insufficiency of existing treatments.
2Productivity
If neutrophils are activated to produce reactive oxygen species to suppress inflammatory reactions, then foreign substances are eliminated, but cellular tissues suffer damaging effects
Solution Approach 1:
The patent converts the harmful excessive activation of neutrophils into a beneficial controlled response. The lysozyme-chitosan complex modulates neutrophil activity to maintain their ability to eliminate foreign substances while preventing excessive reactive oxygen species production that causes tissue damage. This transforms the harmful cytotoxic effect into a controlled, beneficial immune response.
Solution Approach 2:
The lysozyme-chitosan complex acts as an intermediary substance that mediates between the immune system and cellular tissues. It regulates neutrophil activation and reactive oxygen species production, allowing foreign substance elimination while protecting cellular tissues from damaging effects. The complex serves as a bridge that balances immune defense with tissue protection.
3Reliability
If existing treatments are applied to suppress inflammatory reactions, then some inflammatory effects are reduced, but adverse effects on cellular tissues persist
Solution Approach 1:
The patent changes the chemical and physical parameters of the treatment by using a lysozyme-chitosan complex with specific molecular weights and concentration ratios. This optimized composition achieves superior inflammatory suppression while minimizing adverse effects on cellular tissues, overcoming the limitations of existing treatments like glucosamine and plant essential oils.
Solution Approach 2:
The patent employs a composite material consisting of lysozyme and chitosan bound together, which provides synergistic therapeutic effects. This composite approach enhances inflammatory suppression while reducing adverse effects on cellular tissues, addressing the shortcomings of single-substance treatments.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The lysozyme-chitosan complex effectively reduces neutrophil adhesion and reactive oxygen species production, thereby mitigating neutrophil-induced inflammation, including conditions like dermatitis and pyoderma, with additive and synergistic effects from additional active ingredients.
Implementation Method 1
A pharmaceutical composition containing a complex of lysozyme and chitosan bound together, which is produced through the Maillard reaction or cross-linking
Implementation Method 2
suppress neutrophil adhesion and subsequent inflammatory reactions by masking antigenic structures
Data Source
AI summary
The present invention provides a method for treating or preventing inflammation caused by neutrophils and a pharmaceutical composition for such treatment or prevention. Specifically, provided is a pharmaceutical composition or the like for treating or preventing inflammation caused by neutrophils that contains a complex in which lysozyme and chitosan are bonded.